Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NASDAQ:APLS NASDAQ:AVBP NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$84.03+0.9%$79.18$34.34▼$95.32$5.21B0.69958,429 shs47,477 shsAPLSApellis Pharmaceuticals$40.970.0%$29.59$16.10▼$41.05$5.24B-0.244.53 million shs546,216 shsAVBPArriVent BioPharma$29.63-0.7%$25.66$16.10▼$32.14$1.37B1.51494,127 shs80,019 shsXENEXenon Pharmaceuticals$57.86+0.3%$54.09$28.19▼$63.95$5.59B0.651.28 million shs62,187 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+3.15%-2.44%-1.24%+28.38%+111.45%APLSApellis Pharmaceuticals+0.02%-0.05%+1.39%+76.98%+105.06%AVBPArriVent BioPharma-0.53%-0.70%+19.85%+35.41%+43.34%XENEXenon Pharmaceuticals+2.82%+5.84%+1.52%+40.26%+53.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$84.03+0.9%$79.18$34.34▼$95.32$5.21B0.69958,429 shs47,477 shsAPLSApellis Pharmaceuticals$40.970.0%$29.59$16.10▼$41.05$5.24B-0.244.53 million shs546,216 shsAVBPArriVent BioPharma$29.63-0.7%$25.66$16.10▼$32.14$1.37B1.51494,127 shs80,019 shsXENEXenon Pharmaceuticals$57.86+0.3%$54.09$28.19▼$63.95$5.59B0.651.28 million shs62,187 shs7 Stocks to Buy Before SpaceX Goes PublicSpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026. These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+3.15%-2.44%-1.24%+28.38%+111.45%APLSApellis Pharmaceuticals+0.02%-0.05%+1.39%+76.98%+105.06%AVBPArriVent BioPharma-0.53%-0.70%+19.85%+35.41%+43.34%XENEXenon Pharmaceuticals+2.82%+5.84%+1.52%+40.26%+53.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.78Moderate Buy$112.7334.17% UpsideAPLSApellis Pharmaceuticals 2.04Hold$34.89-14.82% DownsideAVBPArriVent BioPharma 2.92Moderate Buy$43.0045.12% UpsideXENEXenon Pharmaceuticals 3.00Buy$73.1326.38% UpsideCurrent Analyst Ratings BreakdownLatest AVBP, APGE, XENE, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026APGEApogee Therapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.005/1/2026APGEApogee Therapeutics Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.004/24/2026AVBPArriVent BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$33.00 ➝ $45.004/20/2026APGEApogee Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AVBPArriVent BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026APLSApellis Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$26.00 ➝ $41.004/8/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026APLSApellis Pharmaceuticals Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/2/2026APLSApellis Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$20.00 ➝ $41.004/1/2026APLSApellis Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$37.00 ➝ $41.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$13.23 per shareN/AAPLSApellis Pharmaceuticals$1.00B5.22$0.21 per share196.04$2.93 per share13.98AVBPArriVent BioPharmaN/AN/AN/AN/A$7.44 per shareN/AXENEXenon Pharmaceuticals$7.50M745.53N/AN/A$7.53 per share7.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$255.84M-$4.22N/AN/AN/AN/A-36.77%-34.87%5/11/2026 (Estimated)APLSApellis Pharmaceuticals$22.39M$0.13315.14N/AN/A2.23%8.20%2.38%5/6/2026 (Estimated)AVBPArriVent BioPharma-$166.31M-$4.41N/AN/AN/AN/A-62.49%-58.11%5/11/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.36N/AN/AN/AN/A-55.81%-52.04%5/11/2026 (Estimated)Latest AVBP, APGE, XENE, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026APGEApogee Therapeutics-$1.12N/AN/AN/AN/AN/A5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88N/AN/AN/AN/AN/A5/11/2026Q1 2026XENEXenon Pharmaceuticals-$1.17N/AN/AN/A$1.36 millionN/A5/6/2026Q1 2026APLSApellis Pharmaceuticals-$0.38N/AN/AN/A$203.58 millionN/A3/5/2026Q4 2025AVBPArriVent BioPharma-$0.87-$0.78+$0.09-$0.78N/AN/A3/2/2026Q4 2025APGEApogee Therapeutics-$1.05-$1.03+$0.02-$1.03N/AN/A2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/A2/24/2026Q4 2025APLSApellis Pharmaceuticals-$0.39$0.47+$0.86-$0.45$199.28 million$199.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AAVBPArriVent BioPharmaN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A26.5726.57APLSApellis Pharmaceuticals0.983.142.70AVBPArriVent BioPharmaN/A12.8312.83XENEXenon PharmaceuticalsN/A13.4113.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%APLSApellis Pharmaceuticals96.29%AVBPArriVent BioPharma9.48%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics24.30%APLSApellis Pharmaceuticals6.80%AVBPArriVent BioPharma18.58%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9161.85 million46.82 millionOptionableAPLSApellis Pharmaceuticals770128.02 million119.32 millionOptionableAVBPArriVent BioPharma4046.37 million37.75 millionN/AXENEXenon Pharmaceuticals21096.64 million92.71 millionOptionableAVBP, APGE, XENE, and APLS HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 6 at 3:15 AM | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on MondayMay 4 at 11:48 AM | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comJennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comPictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comXenon to Report Q1 2026 Financial Results on May 7, 2026April 30, 2026 | globenewswire.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)April 30, 2026 | marketbeat.comXenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton ConferenceApril 26, 2026 | marketbeat.comPeregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENEApril 24, 2026 | marketbeat.comXenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity HereApril 23, 2026 | insidermonkey.comXenon's Phase 3 Supports A 'Buy' Despite Its PremiumApril 22, 2026 | seekingalpha.comXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal ...April 19, 2026 | caledonianrecord.comCXenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026April 19, 2026 | quiverquant.comQXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingApril 19, 2026 | globenewswire.comXenon Pharmaceuticals Inc.April 19, 2026 | edition.cnn.comXenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)April 16, 2026 | marketbeat.comXenon to Present at Upcoming Investor ConferencesApril 15, 2026 | globenewswire.comXenon Expands 2025 Inducement Equity Incentive PlanApril 13, 2026 | tipranks.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by BrokeragesApril 11, 2026 | marketbeat.comXenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual MeetingApril 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVBP, APGE, XENE, and APLS Company DescriptionsApogee Therapeutics NASDAQ:APGE$84.02 +0.74 (+0.88%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Apellis Pharmaceuticals NASDAQ:APLS$40.96 -0.01 (-0.01%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.ArriVent BioPharma NASDAQ:AVBP$29.63 -0.20 (-0.67%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Xenon Pharmaceuticals NASDAQ:XENE$57.86 +0.15 (+0.26%) As of 10:59 AM Eastern This is a fair market value price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
